Ancillary Product Patents to Extend Biologic Patent Life

In 2021, 46% ($260 billion) of all gross prescription drug spending in the US was on biologic products. Patents are government-granted monopolies that last 20 years; by obtaining multiple patents for different aspects of the same product, biologic manufacturers create “patent thickets” that can block or delay biosimilar competition to protect market share

Read more here.